(78), approximately 20% of patients with primary resistance to erlotinib or gefitinib had MET gene amplification, indicating that MET gene amplification may also be one of the causes of primary resistance of NSCLC to first-generation EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.